The Biotech Investor: How to Profit from the Coming Boom in Biotechnology

by Tom Abate (Author)

Editorial Reviews

From Publishers Weekly
With the population aging and eager for medical innovations, the market for
biotechnology is vast. But for investors looking at biotech firms, it can be a
minefield: before a company’s brilliant ideas pan out as profitable products,
they must go through years of costly research and development, clear government
regulatory hurdles and sometimes, as with genetically modified foods, weather
political controversy. This informative and well-written primer will help
individual investors navigate the treacherous terrain of biotech stocks. Abate,
a biotechnology and health care reporter for the San Francisco Chronicle,
provides an overview of each sector of the biotechnology industry and the
leading companies in it, tells where to find up-to-date information on the
scientific and medical developments that drive the market, and explains how to
evaluate the financial prospects of the often shaky start-ups that crowd the
field. His advice is appropriately cautious; he suggests putting no more than
20% of a portfolio in biotechnology, and waiting until a company is in hailing
distance of profitability before investing. While the book is pitched at the
non-professional, Abate makes it clear that these speculative, volatile and
often over-sold stocks demand more effort—he recommends reading scientific
journals, attending conferences and perusing the patent literature —than a
complacent mutual-fund investor is used to. But for those willing to brave the
new world of biotechnology, this is a good place to start. 20 charts and graphs.

From Booklist
For investors having a hard time grasping concepts in computer technology, the
biotechnology business is even more mystifying. With futuristic names like
Genentech, Protein Design Labs, and Human Genome Sciences, an excruciatingly
long product development cycle, and very light coverage by analysts, this sector
is one of the most difficult for the stock-buying public to understand. However,
despite a few public mishaps of their own, biotech stocks as a whole have held
up better through the downturn than the overall tech sector. Abate is one of the
few writers who closely watch this area, and writes the "BioScope" column for
the San Francisco Chronicle. He admits that biotech stocks are among some of the
most difficult to play, and warns against jumping into any of the speculative
startups in this field. Instead he recommends most investors stick to the
handful of companies that have already shown a profit. With plenty of charts and
detailed coverage of many individual companies, this would be an excellent
source to begin research on this area of cutting-edge medicine.

Product Details

Paperback: 304 pages
Publisher: Holt Paperbacks (January 1, 2004)
Language: English
ISBN-10: 0805075089



Promoting Natural Foods, Natural Organic Farming, Natural Healing,
 Natural Lifestyles and Freedom of Choice in Holistic Healthcare